Treatment toxicities and pathological response through the evolution of neoadjuvant regimens in early triple-negative breast cancer.

ABSTRACT:

Background

Pembrolizumab-based neoadjuvant chemoimmunotherapy (CIT) is the new standard of care for high-risk early triple-negative breast cancer (eTNBC). The addition of multiple cytotoxic drugs can lead to cumulative toxicities. We report the evolution of chemotherapy (CT) practice and its impact on completion and effectiveness of subsequent regimens in a real-world setting.

Patients and methods

We conducted an ambispective, observational study of patients with eTNBC at a comprehensive cancer centre between February 2019 and February 2024. All data were extracted from electronic health records and manually curated.

Results

Of the 366 patients enrolled, 247 received neoadjuvant CT and 119 received CIT. Grade 3/4 toxicities were more common in the CIT group (78.2% ver

SUBMITTER: Arnaud E 

PROVIDER: S-EPMC12836798 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature